Well Health Technologies Corp. · TSX:WELL
Well Health Technologies — Q4 2024 Earnings Presentation
26 slides from Well Health Technologies's earnings presentation, April 2025
Slide 1: Q4 2024 Earnings Presentation
%% 80? WELL Health ee ee TECHNOLOGIES CORP Q4 2024 Earnings Presentation
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward- looking statement
Slide 3: Update on Circle Medical and Filing
Update on Circle Medical and Filing OC Circle Medical oe ‘eo += TECHNOLOGIES CORP
Slide 4: Change Healthcare Cybersecurity Impact on CRH
Change Healthcare Cybersecurity Impact on CRH CRH Medical CORPORATION 0%. WELL Health TECHNOLOGIES CORP
Slide 5: FY 2024 Financial Highlights – Revenue
FY 2024 Financial Highlights – Revenue Revenue (IFRS) Excluding Rev. Rec. Impact (C$ in millions) (C$ in millions) 1,200,000 1,200,000 224,723 1,000,049 1,000,000 919,688 1,000,000 +29% -56,554 -24,535 800,000 776,054 800,000 776,054 600,000 600,000 400,000 400,000 200,000 200,000 0 2023 2024 Growth
Slide 6: FY 2024 Financial Highlights – Adjusted EBITDA
FY 2024 Financial Highlights –Adjusted EBITDA Adj. EBITDA (IFRS) Excluding Rev. Rec. Impact (C$ in millions) (C$ in millions) 140,000 140,000 13,632 120,000 113,394 130,000 127,026 +12% 100,000 120,000 113,394 80,000 110,000 -56,554 100,000 60,000 46,665 -23,807 90,000 40,000 80,000 20,000 70,000 0
Slide 7: WELL FY 2024 Key Financial Highlights
WELL FY 2024 Key Financial Highlights 2024 Revenue 2024 Net Income 2024 FCFA2S1 $919.7M $29.1M $49.3M Y/Y Y/Y Y/Y +19% +75% +15% FCFA2S Per Share WELL Canada Revenue WELL Canada EBITDA Growth Growth 20.0¢ Total Organic Y/Y Y/Y +30% +20% +22% +11% 1) Please refer to the Earnings Release for the defin
Slide 8: WELL FY 2024 Operational Highlights
WELL FY 2024 Operational Highlights 4,100+ 41,000+ 8.7M+ Total Care Interactions Providers in WELL's Clinic Unique Providers supported +37% YoY Network by WELL's Technology (+34% organic) 5.7M+ +35% 28% Patient visits YoY US patient visits growth YoY CAN patient visit growth +32% YoY (all organic) (
Slide 9: 2025 Annual Guidance
2025 Annual Guidance 2025 Guidance Commentary • Includes: Circle Medical over 90% of deferred revenue expected in 2025, with remainder in fiscal 2026 Revenue(1) • Expecting 8% realized in Q1, 28% in Q2, 32% in Q3, 26% in Q4 $1.40B to $1.45B • $6.7M has been recognized as at April 14 • Does not inclu
Slide 10: The WELL Health Family
The WELL Health Family WELL Health Technologies Corp. TSX: WELL I I 1 Canadian Clinics |_| WELL Health USA (Puture IPO) HO AIDX Cybersecurity Primary Care CRH Anesthesia Diagnostics Provider Staffing i SS Wisp I H Sale Process | I Underway 1 T Circle Medical H l a TECHNOLOGIES CORP
Slide 11: 2024 Annual Earnings – Additional Topics to be Covered
2024 Annual Earnings – Additional Topics to be Covered Key updates on the following: 1. HEALWELL AI 2. WELLSTAR and “Buy Canadian” 3. Canadian Clinics Update 4. Strategic Sales Processes at Wisp and Circle Medical
Slide 12: HEALWELL Overview
TSX: AIDX HEALWELL Overview HEALWELL’s acquisition of Orion Health creates global Headquarters TORONTO, ON market leader in healthcare data interoperability and AI Established Commercial Clients. Inclusive of 7 of the top # of Employees1: 750+ 10 largest big pharma companies. Robust M&A strategy and
Slide 13: Orion Health Overview
TSX: AIDX Orion Health Overview Unified Healthcare Platform allows data to flow seamlessly across the healthcare ecosystem, revealing insights from health records, and empowering people to take control of their own healthcare Revenue Run Rate: C$100M+ 70+ Sites Worldwide, Covering ~150M+ Patient Rec
Slide 14: 70+ Sites Worldwide, Covering ~150M+ Patient Records
TSX: AIDX 70+ Sites Worldwide, Covering ~150M+ Patient Records
Slide 15: Large Referenceable Customers
TSX: AIDX | Large Referenceable Customers Ontario, Canada Abu Dhabi, Middle East Alberta, Canada • DFD delivered to a • First DCR in the Middle East • 20+ year partnership Saudi Arabia population of 15 million Region, connecting 100% of delivering province-wide DCR • Delivery underway of DCR hospita
Slide 16: WELLSTAR at a Glance
WELLSTAR at a Glance WELLSTAR exists to enable healthcare practitioners to provide the highest-quality care with best-in-class technology and services S Revenue C$70M+ Revenue Run-Rate Gross Margin 80%+ LTM 41,000+ Practitioners purchase products / services SCALE > 5 E 2 E ira) = < 2 E a rs 6 fe) 4
Slide 17: WELLSTAR’s Path to Go-Public
WELLSTAR’s Path to Go-Public ✓ ✓ 17
Slide 18: Buy Canadian
Buy Canadian WELL’s Public Sector Pipeline Current Policies 350 $300M 300 250 200 . 150 $100M 100 50 WELL’s Positioning 0 2023 2025 18
Slide 19: WELL Canadian Clinics Revenue and Adj. EBITDA Growth
WELL Canadian Clinics WELL Canadian Clinics WELL Canadian Clinics Count Revenue Growth Adj. EBITDA Growth (C$ in 000s) (C$ in 000s) 350,000 45,000 230 319,135 40,699 210 40,000 210 300,000 190 35,000 33,085 250,000 167 230,381 170 30,000 150 142 200,000 25,000 24,196 182,098 128 130 20,000 150,000 1
Slide 20: Clinic Acquisitions Q4-2024 and Q1-2025
Q4-2024 Q1-2025 +20 Clinics (1) +11 Clinics 4 transactions 4 transactions +$30.8M +$31.5M Annual Revenue Annual Revenue +111 Providers (1) +71 Providers Total Canadian Clinics Total Canadian Clinics 1) This figure only includes clinics that are owned and operated by WELL, and the physicians that wor
Slide 21: Clinic Pipeline: Signed LOIs
Under LOI: $31M 5 5 Canadian Clinics Revenue Signed LOIs Clinics Under LOI: $40M 7 Total WELL Revenue Signed LOIs Total WELL $390M 35+ 130+ Pipeline1 Revenue Targets Engaged Clinics 1. The Total WELL Pipeline includes potential deals that are either under LOI or in the pre-LOI stage.
Slide 22: ROIC and Adj. EBITDA Growth by Business
Pre-Tax Unlevered ROIC Adj. EBITDA Growth 60,000 56,313 11% 50,000 +22% WELLSTAR 45,960 40,000 12% 30,000 WELL Health Diagnostics 20,000 22% 10,000 Primary Care - Historic 0 2023 2024 30% 25%+ Primary Care - 3yr Cohort(1) Expected Adj. EBITDA growth in 2025(2) 1) The 3 year cohort refers to clinics
Slide 23: Update on Wisp and Circle Sale Processes
Update on Wisp and Circle Sale Processes wisp OQ Circle Medical 0%. WELL Health TECHNOLOGIES CORP
Slide 24: FY 2024 Financial Highlights – Net Income
FY 2024 Financial Highlights – Net Income Revenue recognition impacts from Circle Medical and CRH had a material impact on 2024 Net Income (C$ in 000s) 100,000 20,001 89,746 90,000 80,000 40,719 70,000 60,000 50,000 40,000 30,000 29,026 20,000 10,000 0 2024 Rev Rec Rev Rec 2024 Exc. (CM) (CRH) Rev R
Slide 25: Outlook: 2025 and Beyond
Outlook: 2025 and Beyond 2025 Guidance: WELLSTAR IPO WELL Canada $1.40-1.45B Revenue 2026 Revenue Target >25% Adj. EBITDA $190-210M Adj. EBITDA >$100M Growth(1) for 2025 WELL Canada HEALWELL Wisp & Circle: 2-Yr Target(1) of Consolidation of Committed to >$800M Revenue $120M Revenue in 2025 Sale Proc
Slide 26: Contact
° WELL Health TECHNOLOGIES CORP Contact Hamed Shahbazi CEO, Chairman & Founder hamed@well.company Tyler Baba Investor Relations investor@well.company www.well.company 550-375 Water Street Vancouver, BC V6B 5C6 Canada
WELL Health Technologies — Q4 2024 Earnings Presentation on 6ix